AGEN2373

DRUG2 trials

Sponsors

Agenus Inc., Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Conditions

Advanced CancerPancreatic Cancer

Phase 1

Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer

CompletedNCT04121676

Agenus Inc.Advanced Cancer

Start: 2019-09-26End: 2024-11-30Updated: 2025-01-13

Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer

RecruitingNCT06782932

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPancreatic Cancer

Start: 2025-05-27End: 2028-12-31Target: 38Updated: 2025-12-03

Related Papers

A phase 1 study of AGEN2373, a novel CD137 agonist antibody designed to avoid hepatoxicity, in patients with advanced solid tumors.

Journal of Clinical Oncology2023-06-014 citations

Initial findings of the first-in-human phase I study of AGEN2373, a conditionally active CD137 agonist antibody, in patients (pts) with advanced solid tumors.

Journal of Clinical Oncology2021-05-2031 citations

377 AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and FcγR co-targeting to promote antitumor immunologic effects

Regular and Young Investigator Award Abstracts2020-11-017 citations